These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 9558037)

  • 1. Inhibition of human gastric lipase secretion by glucagon-like peptide-1.
    Wøjdemann M; Wettergren A; Sternby B; Holst JJ; Larsen S; Rehfeld JF; Olsen O
    Dig Dis Sci; 1998 Apr; 43(4):799-805. PubMed ID: 9558037
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man.
    Wettergren A; Schjoldager B; Mortensen PE; Myhre J; Christiansen J; Holst JJ
    Dig Dis Sci; 1993 Apr; 38(4):665-73. PubMed ID: 8462365
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The inhibitory effect of glucagon-like peptide-1 (GLP-1) 7-36 amide on gastric acid secretion in humans depends on an intact vagal innervation.
    Wettergren A; Wøjdemann M; Meisner S; Stadil F; Holst JJ
    Gut; 1997 May; 40(5):597-601. PubMed ID: 9203936
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lack of effect of synthetic human gastric inhibitory polypeptide and glucagon-like peptide 1 [7-36 amide] infused at near-physiological concentrations on pentagastrin-stimulated gastric acid secretion in normal human subjects.
    Nauck MA; Bartels E; Orskov C; Ebert R; Creutzfeldt W
    Digestion; 1992; 52(3-4):214-21. PubMed ID: 1459356
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GLP-1 (glucagon-like peptide 1) and truncated GLP-1, fragments of human proglucagon, inhibit gastric acid secretion in humans.
    Schjoldager BT; Mortensen PE; Christiansen J; Orskov C; Holst JJ
    Dig Dis Sci; 1989 May; 34(5):703-8. PubMed ID: 2714145
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glucagon-like peptide-1 7-36 amide and peptide YY have additive inhibitory effect on gastric acid secretion in man.
    Wettergren A; Maina P; Boesby S; Holst JJ
    Scand J Gastroenterol; 1997 Jun; 32(6):552-5. PubMed ID: 9200286
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of glucagon-like peptide-1 on gastric somatostatin and gastrin secretion in the rat.
    Eissele R; Koop H; Arnold R
    Scand J Gastroenterol; 1990 May; 25(5):449-54. PubMed ID: 1972810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of sham feeding-stimulated human gastric acid secretion by glucagon-like peptide-2.
    Wøjdemann M; Wettergren A; Hartmann B; Hilsted L; Holst JJ
    J Clin Endocrinol Metab; 1999 Jul; 84(7):2513-7. PubMed ID: 10404829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glucagon-like peptide-1 7-36 amide and peptide YY from the L-cell of the ileal mucosa are potent inhibitors of vagally induced gastric acid secretion in man.
    Wettergren A; Petersen H; Orskov C; Christiansen J; Sheikh SP; Holst JJ
    Scand J Gastroenterol; 1994 Jun; 29(6):501-5. PubMed ID: 7915853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glucagon-like peptide-1-(7-36) amide and peptide YY mediate intraduodenal fat-induced inhibition of acid secretion in dogs.
    Fung LC; Chisholm C; Greenberg GR
    Endocrinology; 1998 Jan; 139(1):189-94. PubMed ID: 9421414
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans.
    Nauck MA; Niedereichholz U; Ettler R; Holst JJ; Orskov C; Ritzel R; Schmiegel WH
    Am J Physiol; 1997 Nov; 273(5):E981-8. PubMed ID: 9374685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is glucagon-like peptide 1 an incretin hormone?
    Nauck MA
    Diabetologia; 1999 Mar; 42(3):373-9. PubMed ID: 10096792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Erythromycin antagonizes the deceleration of gastric emptying by glucagon-like peptide 1 and unmasks its insulinotropic effect in healthy subjects.
    Meier JJ; Kemmeries G; Holst JJ; Nauck MA
    Diabetes; 2005 Jul; 54(7):2212-8. PubMed ID: 15983224
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of human gastric lipase by intraduodenal fat involves glucagon-like peptide-1 and cholecystokinin.
    Wøjdemann M; Riber C; Bisgaard T; Sternby B; Larsen S; Rehfeld JF; Holst JJ; Olsen O
    Regul Pept; 1999 Apr; 80(3):101-6. PubMed ID: 10425652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glucagon-like peptide-1 inhibits gastropancreatic function by inhibiting central parasympathetic outflow.
    Wettergren A; Wøjdemann M; Holst JJ
    Am J Physiol; 1998 Nov; 275(5):G984-92. PubMed ID: 9815028
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glucagon-like peptide-1 (7-36)-NH2: a physiological inhibitor of gastric acid secretion in man.
    O'Halloran DJ; Nikou GC; Kreymann B; Ghatei MA; Bloom SR
    J Endocrinol; 1990 Jul; 126(1):169-73. PubMed ID: 2380653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glucagon-like peptide I reduces postprandial glycemic excursions in IDDM.
    Dupre J; Behme MT; Hramiak IM; McFarlane P; Williamson MP; Zabel P; McDonald TJ
    Diabetes; 1995 Jun; 44(6):626-30. PubMed ID: 7789625
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients.
    Willms B; Werner J; Holst JJ; Orskov C; Creutzfeldt W; Nauck MA
    J Clin Endocrinol Metab; 1996 Jan; 81(1):327-32. PubMed ID: 8550773
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glucagon-like peptide 1 increases the period of postprandial satiety and slows gastric emptying in obese men.
    Näslund E; Gutniak M; Skogar S; Rössner S; Hellström PM
    Am J Clin Nutr; 1998 Sep; 68(3):525-30. PubMed ID: 9734726
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pertussis toxin-sensitive inhibition of glucagon-like peptide 1-stimulated acid production by epidermal growth factor and transforming growth factor alpha in rat parietal cells.
    Schmidtler J; Dehne K; Schusdziarra V; Classen M; Schepp W
    Eur J Pharmacol; 1993 Jun; 246(1):59-66. PubMed ID: 8394819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.